| Figure 1‑1: Urological Device Market Share Ranking by Segment, U.S., 2023 (1 of 2) |
| Figure 1‑2: Urological Device Market Share Ranking by Segment, U.S., 2023 (2 of 2) |
| Figure 1‑3: Companies Researched in This Report (1 of 2) |
| Figure 1‑4: Companies Researched in This Report (2 of 2) |
| Figure 1‑5: Factors Impacting the Urological Device Market by Segment, U.S. (1 of 2) |
| Figure 1‑6: Factors Impacting the Urological Device Market by Segment, U.S. (2 of 2) |
| Figure 1‑7: Recent Events in the Urological Device Market, U.S., 2020 – 2024 |
| Figure 1‑8: Urological Device Procedures Covered (1 of 3) |
| Figure 1‑9: Urological Device Procedures Covered (2 of 3) |
| Figure 1‑10: Urological Device Procedures Covered (3 of 3) |
| Figure 1‑11: Procedure Codes Investigated |
| Figure 1‑12: Urological Device Markets Covered (1 of 6) |
| Figure 1‑13: Urological Device Markets Covered (2 of 6) |
| Figure 1‑14: Urological Device Markets Covered (3 of 6) |
| Figure 1‑15: Urological Device Markets Covered (4 of 6) |
| Figure 1‑16: Urological Device Markets Covered (5 of 6) |
| Figure 1‑17: Urological Device Markets Covered (6 of 6) |
| Figure 1‑18: Key Report Updates |
| Figure 1‑19: Version History |
| Figure 2‑1: Urological Device Market by Segment, Worst Case Scenario, U.S., 2020 – 2030 (US$M) (1 of 2) |
| Figure 2‑2: Urological Device Market by Segment, Worst Case Scenario, U.S., 2020 – 2030 (US$M) (2 of 2) |
| Figure 2‑3: Urological Device Market by Segment, Base Case Scenario, U.S., 2020 – 2030 (US$M) (1 of 2) |
| Figure 2‑4: Urological Device Market by Segment, Base Case Scenario, U.S., 2020 – 2030 (US$M) (2 of 2) |
| Figure 2‑5: Urological Device Market by Segment, Best Case Scenario, U.S., 2020 – 2030 (US$M) (1 of 2) |
| Figure 2‑6: Urological Device Market by Segment, Best Case Scenario, U.S., 2020 – 2030 (US$M) (2 of 2) |
| Figure 4‑1: Urinary Incontinence Treatments by Company (1 of 2) |
| Figure 4‑2: Urinary Incontinence Treatments by Company (2 of 2) |
| Figure 4‑3: Stone Management Devices by Company (1 of 4) |
| Figure 4‑4: Stone Management Devices by Company (2 of 4) |
| Figure 4‑5: Stone Management Devices by Company (3 of 4) |
| Figure 4‑6: Stone Management Devices by Company (4 of 4) |
| Figure 4‑7: BPH Treatments by Company |
| Figure 4‑8: Urological Endoscopes by Company (1 of 2) |
| Figure 4‑9: Urological Endoscopes by Company (2 of 2) |
| Figure 4‑10: Prostate Cancer Treatments by Company |
| Figure 4‑11: Urodynamic Equipment and Consumables by Company |
| Figure 4‑12: Nephrostomy Devices by Company |
| Figure 4‑13: Men’s Reproductive Health Devices by Company |
| Figure 4‑14: Urinary Guidewires by Company |
| Figure 4‑15: Class 2 Device Recall BARD Magic3 GO |
| Figure 4‑16: Class 2 Device Recall BULKAMID, URETHRAL BULKING SYSTEM |
| Figure 4‑17: Class 2 Device Recall COAPTITE |
| Figure 4‑18: Class 2 Device Recall Medline Silicone Foley catheter |
| Figure 4‑19: Class 2 Device Recall SureStep |
| Figure 4‑20: Class 2 Device Recall AMS 700 100 mL Spherical Reservoir with InhibiZone |
| Figure 4‑21: Class 3 Device Recall Teleflex MEDICAL RuSCH One piece Male External Medium Catheter W/O Tape |
| Figure 4‑22: Class 2 Device Recall AMS 800 Artificial Urinary Sphincter AMS 800 Belt Cuff |
| Figure 4‑23: Class 3 Device Recall RUSCH Urinary Drainage bag |
| Figure 4‑24: Class 2 Device Recall Rusch EasyCath Kit |
| Figure 4‑25: Class 2 Device Recall UroPass Ureteral Access Sheath |
| Figure 4‑26: Class 2 Device Recall Cook Medical Kwart RetroInject Ureteral Stent |
| Figure 4‑27: Class 2 Device Recall Contour VL Ureteral Stent Set |
| Figure 4‑28: Class 2 Device Recall Cook Medical |
| Figure 4‑29: Class 2 Device Recall Polaris Ultra Ureteral Stent Set |
| Figure 4‑30: Class 2 Device Recall Percuflex Plus Ureteral Stent Set |
| Figure 4‑31: Class 2 Device Recall Stretch VL Ureteral Stent Set |
| Figure 4‑32: Class 2 Device Recall Universa Firm Ureteral Stent |
| Figure 4‑33: Class 2 Device Recall Universa Soft Ureteral Stent |
| Figure 4‑34: Class 2 Device Recall SofFlex Double Pigtail Ureteral Stent |
| Figure 4‑35: Class 2 Device Recall Urolift System |
| Figure 4‑36: Class 3 Device Recall GreenLight HPSEA Laser Fibers |
| Figure 4‑37: Class 2 Device Recall MoXy Laser Fiber |
| Figure 4‑38: Class 2 Device Recall AURIGA 30 BRAZIL ZERO COST SYSTEM |
| Figure 4‑39: Class 2 Device Recall Dornier |
| Figure 4‑40: Class 2 Device Recall Olympus |
| Figure 4‑41: Class 2 Device Recall OLYMPUS HF Resection Electrodes |
| Figure 4‑42: Class 2 Device Recall KARL STORZ Flexible Video CystoUrethroscopes (CVIEW) |
| Figure 4‑43: Class 2 Device Recall Flexible Cystoscope |
| Figure 4‑44: Class 2 Device Recall SpaceOAR Vue System |
| Figure 4‑45: Class 2 Device Recall IcePearl 2.1 CX 90 Cyroablation Needles |
| Figure 4‑46: Class 2 Device Recall IceSphere" Cryoablation Needles |
| Figure 4‑47: Class 2 Device Recall VisualICE MRI MCP |
| Figure 4‑48: Class 2 Device Recall Visual ICE Cryoablation System |
| Figure 4‑49: Class 2 Device Recall Percutaneous Neonatal Pigtail Nephrostomy Set and Pediatric Nephrostomy Stent Set |
| Figure 4‑50: Class 2 Device Recall Percutaneous Pigtail Nephrostomy Set |
| Figure 4‑51: Class 2 Device Recall Percutaneous Malecot Nephrostomy Set |
| Figure 4‑52: Class 2 Device Recall Percutaneous Entry Set |
| Figure 4‑53: Class 2 Device Recall Torosa |
| Figure 4‑54: Class 2 Device Recall the AMS 700 Inflatable Penile Prosthesis |
| Figure 4‑55: Class 2 Device Recall Titan Pump |
| Figure 4‑56: Class 2 Device Recall AMS 700 Inflatable Penile Prosthesis |
| Figure 4‑57: Class 2 Device Recall AMS 700 100 mL Spherical Reservoir with InhibiZone |
| Figure 4‑58: Post-Market Clinical Follow-Up on TVT EXACT® Continence System |
| Figure 4‑59: Single-incision Versus Retropubic Mid-Urethral Sling (Solyx) for SUI during Minimally Invasive Sacrocolpopexy (SASS) |
| Figure 4‑60: Artificial Urinary Sphincter Clinical Outcomes (AUSCO) |
| Figure 4‑61: e۰Sense® Catheter Clinical Investigation |
| Figure 4‑62: Investigation of Non-CE Marked Intermittent Catheters for Females |
| Figure 4‑63: Exploratory Study of a New Urine Collection Device for Men |
| Figure 4‑64: Investigation of New Intermittent Catheters in Healthy Volunteers |
| Figure 4‑65: Safety and Device Performance of the Uriprene® Degradable Temporary Ureteral Stent Following Uncomplicated Ureteroscopy (URIPRENE) |
| Figure 4‑66: The RELIEF™ Ureteral Stent - Assessment of Retrograde Urinary Reflux and Distal Coil Bladder Position |
| Figure 4‑67: Double-J PLUS Postmarket Registry |
| Figure 4‑68: A Randomized, International Study to Assess the Safety of iTind Compared to UroLift |
| Figure 4‑69: Comparing UroLift Experience Against Rezūm |
| Figure 4‑70: A Study Comparing Urolift and TURP Ahead of Radiotherapy in Men with Urinary Symptoms Secondary to Prostate Enlargement |
| Figure 4‑71: UroLift System with SAbR for Prostate Cancer and BPH |
| Figure 4‑72: Comparing UroLift Experience Against Rezūm (CLEAR) |
| Figure 4‑73: To Evaluate the Feasibility, Preliminary Safety and Performance of Rezūm System in BPH Treatment in China |
| Figure 4‑74: Evaluation of Novel Disposable Flexible Ureteroscope for the Treatment of Renal Calculi |
| Figure 4‑75: Prospective Evaluation of the LithoVue Elite Ureteroscope |
| Figure 4‑76: Effectiveness of Ambu® aScope™ 4 Cysto With the aView™ 2 Advance for Flexible Cystoscopy |
| Figure 4‑77: Single-use Cystoscope System for Direct Visualization of the Urethra and Bladder |
| Figure 4‑78: Evaluation of Performance and Safety of Ambu® aScope™ 4 Cysto and aView™ Urologia for Flexible Cystoscopy |
| Figure 4‑79: Multi-omic Approach to Study HDR Brachytherapy for Favorable Risk and Low Tier Intermediate Risk Prostate Cancer |
| Figure 4‑80: Focal Ablation with Focal Cryotherapy or HIFU for the Treatment of Men with Localized Prostate Cancer |
| Figure 4‑81: Using Rectal Hydrogel Spacer for Salvage SABR in Prostate Cancer |
| Figure 4‑82: LDR vs. HDR Brachytherapy for Prostate Cancer (LDR/HDRmono) |
| Figure 4‑83: Rectal Spacer Hydrogel Before Radiation Therapy in Reducing Radiation Dose to the Rectum in Patients with Prostate Cancer |
| Figure 4‑84: Prospective Observational Study on SEBBIN Silicone Gel-filled Testicular Implants |
| Figure 4‑85: Penile Prosthesis in Patients with Erectile Dysfunction |
| Figure 4‑86: Safety and Efficacy Study of USTRAP™ in Male Urinary Incontinence (PROSPECT) |
| Figure 4‑87: Rigicon Infla10® Three-Piece Inflatable Penile Prosthesis |
| Figure 5‑1: Urological Device Market by Segment, U.S., 2020 – 2030 (US$M) (1 of 2) |
| Figure 5‑2: Urological Device Market by Segment, U.S., 2020 – 2030 (US$M) (2 of 2) |
| Figure 5‑3: Leading Competitors, Urological Device Market, U.S., 2023 (1 of 2) |
| Figure 5‑4: Leading Competitors, Urological Device Market, U.S., 2023 (2 of 2) |
| Figure 5‑5: SWOT Analysis, Becton Dickinson |
| Figure 5‑6: SWOT Analysis, Boston Scientific |
| Figure 5‑7: SWOT Analysis, Cardinal Health |
| Figure 5‑8: SWOT Analysis, Coloplast |
| Figure 5‑9: SWOT Analysis, Cook Medical |
| Figure 5‑10: SWOT Analysis, Elekta |
| Figure 5‑11: SWOT Analysis, Ethicon |
| Figure 5‑12: SWOT Analysis, Karl Storz |
| Figure 5‑13: SWOT Analysis, Laborie |
| Figure 5‑14: SWOT Analysis, Medline |
| Figure 5‑15: SWOT Analysis, Olympus |
| Figure 5‑16: SWOT Analysis, Siemens |
| Figure 5‑17: SWOT Analysis, Teleflex |
| Figure 6‑1: Procedure Codes Investigated, U.S., 2023 |
| Figure 6‑2: Urological Procedures by Segment, U.S., 2020 – 2030 (1 of 2) |
| Figure 6‑3: Urological Procedures by Segment, U.S., 2020 – 2030 (2 of 2) |
| Figure 6‑4: Urinary Incontinence Management Procedures by Segment, U.S., 2020 – 2030 |
| Figure 6‑5: Male Urinary Incontinence Management Procedures by Segment, U.S., 2020 – 2030 |
| Figure 6‑6: Female Urinary Incontinence Management Procedures by Segment, U.S., 2020 – 2030 |
| Figure 6‑7: Stone Management Procedures by Segment, U.S., 2020 – 2030 |
| Figure 6‑8: ESWL Procedures, U.S., 2020 – 2030 |
| Figure 6‑9: Transurethral Procedures by Segment, U.S., 2020 – 2030 |
| Figure 6‑10: Ureteral Stent Procedures, U.S., 2020 – 2030 |
| Figure 6‑11: PCNL Procedures, U.S., 2020 – 2030 |
| Figure 6‑12: Ureteroscopy Procedures by Device Type, U.S., 2020 – 2030 |
| Figure 6‑13: Cystoscopy Procedures by Device Type, U.S., 2020 – 2030 |
| Figure 6‑14: BPH Patient Statistics, U.S., 2020 – 2030 |
| Figure 6‑15: BPH Procedures by Segment, U.S., 2020 – 2030 (1 of 2) |
| Figure 6‑16: BPH Procedures by Segment, U.S., 2020 – 2030 (2 of 2) |
| Figure 6‑17: BPH Procedures by Care Setting, U.S., 2020 – 2030 |
| Figure 6‑18: BPH Procedures by Care Setting (Hospital), U.S., 2020 –2030 (1 of 2) |
| Figure 6‑19: BPH Procedures by Care Setting (Hospital), U.S., 2020 –2030 (2 of 2) |
| Figure 6‑20: BPH Procedures by Care Setting (ASC), U.S., 2020 –2030 (1 of 2) |
| Figure 6‑21: BPH Procedures by Care Setting (ASC), U.S., 2020 –2030 (2 of 2) |
| Figure 6‑22: BPH Procedures by Care Setting (Office), U.S., 2020 –2030 (1 of 2) |
| Figure 6‑23: BPH Procedures by Care Setting (Office), U.S., 2020 –2030 (2 of 2) |
| Figure 6‑24: BPH Patient Statistics, U.S., 2020 – 2030 |
| Figure 6‑25: Prostate Cancer Treatment Procedures by Segment, U.S., 2020 – 2030 |
| Figure 6‑26: Watchful Waiting Procedures, U.S., 2020 – 2030 |
| Figure 6‑27: Prostatectomy Procedures by Segment, U.S., 2020 – 2030 |
| Figure 6‑28: Open Prostatectomy Procedures by Segment, U.S., 2020 – 2030 |
| Figure 6‑29: Ablation Procedures by Segment, U.S., 2020 – 2030 |
| Figure 6‑30: Radiation Therapy Procedures by Segment, U.S., 2020 – 2030 |
| Figure 6‑31: HDR Brachytherapy Procedures by Segment, U.S., 2020 – 2030 |
| Figure 6‑32: LDR Brachytherapy Procedures by Segment, U.S., 2020 – 2030 |
| Figure 6‑33: External Radiation Therapy Procedures by Segment, U.S., 2020 – 2030 |
| Figure 6‑34: Urodynamic Testing Procedures by Segment, U.S., 2020 – 2030 |
| Figure 6‑35: Cystometrogram Procedures by Segment, U.S., 2020 – 2030 |
| Figure 6‑36: Uroflowmetry Procedures by Segment, U.S., 2020 – 2030 |
| Figure 6‑37: Nephrostomy Procedures by Segment, U.S., 2020 – 2030 |
| Figure 6‑38: Erectile Dysfunction Management Procedures by Segment, U.S., 2020 – 2030 |
| Figure 7‑1: Urinary Incontinence Device Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 7‑2: Urinary Catheter Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 7‑3: Intermittent Catheter Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 7‑4: Total Intermittent Catheter Market, U.S., 2020 – 2030 |
| Figure 7‑5: Coated Intermittent Catheter Market, U.S., 2020 – 2030 |
| Figure 7‑6: Uncoated Intermittent Catheter Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 7‑7: Uncoated Latex-Free Intermittent Catheter Market, U.S., 2020 – 2030 |
| Figure 7‑8: Uncoated Latex Intermittent Catheter Market, U.S., 2020 – 2030 |
| Figure 7‑9: Closed-System Intermittent Catheter Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 7‑10: Gel Closed-System Intermittent Catheter Market, U.S., 2020 – 2030 |
| Figure 7‑11: Hydrophilic and Antimicrobial Closed-System Intermittent Catheter Market, U.S., 2020 – 2030 |
| Figure 7‑12: Foley Catheter Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 7‑13: Total Foley Catheter Market, U.S., 2020 – 2030 |
| Figure 7‑14: Latex Foley Catheter Market, U.S., 2020 – 2030 |
| Figure 7‑15: Latex-Free Foley Catheter Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 7‑16: Total Latex-Free Foley Catheter Market, U.S., 2020 – 2030 |
| Figure 7‑17: Uncoated Latex-Free Foley Catheter Market, U.S., 2020 – 2030 |
| Figure 7‑18: Coated Latex-Free Foley Catheter Market, U.S., 2020 – 2030 |
| Figure 7‑19: Closed-System Foley Tray Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 7‑20: Total Closed-System Foley Tray Market, U.S., 2020 – 2030 |
| Figure 7‑21: Conventional Closed-System Foley Tray Market, U.S., 2020 – 2030 |
| Figure 7‑22: Antimicrobial Closed-System Foley Tray Market, U.S., 2020 – 2030 |
| Figure 7‑23: External Catheter Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 7‑24: Total External Catheter Market, U.S., 2020 – 2030 |
| Figure 7‑25: Male External Catheter Market, U.S., 2020 – 2030 |
| Figure 7‑26: Female External Catheter Market, U.S., 2020 – 2030 |
| Figure 7‑27: Urethral Bulking Agent Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 7‑28: Total Urethral Bulking Agent Market, U.S., 2020 – 2030 |
| Figure 7‑29: Male Urethral Bulking Agent Market, U.S., 2020 – 2030 |
| Figure 7‑30: Female Urethral Bulking Agent Market, U.S., 2020 – 2030 |
| Figure 7‑31: Incontinence Management Device Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 7‑32: Total Incontinence Management Device Market, U.S., 2020 – 2030 |
| Figure 7‑33: Female Incontinence Sling Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 7‑34: Total Female Incontinence Sling Market, U.S., 2020 – 2030 |
| Figure 7‑35: Transvaginal Tape Female Incontinence Sling Market, U.S., 2020 – 2030 |
| Figure 7‑36: Transobturator Female Incontinence Sling Market, U.S., 2020 – 2030 |
| Figure 7‑37: Single-Incision Female Incontinence Sling Market, U.S., 2020 – 2030 |
| Figure 7‑38: Male Implantable Incontinence Device Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 7‑39: Total Male Implantable Incontinence Device Market, U.S., 2020 – 2030 |
| Figure 7‑40: Male Incontinence Sling Market, U.S., 2020 – 2030 |
| Figure 7‑41: Male Artificial Urinary Sphincter Market, U.S., 2020 – 2030 |
| Figure 7‑42: Urinary Bag Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 7‑43: Total Urinary Bag Market, U.S., 2020 – 2030 |
| Figure 7‑44: Bedside Urine Drainage Bag Market, U.S., 2020 – 2030 |
| Figure 7‑45: Leg Urine Drainage Bag Market, U.S., 2020 – 2030 |
| Figure 7‑46: Leading Competitors, Urinary Incontinence Device Market, U.S., 2023 |
| Figure 7‑47: Leading Competitors, Urinary Catheter Market, U.S., 2023 |
| Figure 7‑48: Leading Competitors, Incontinence Management Device Market, U.S., 2023 |
| Figure 8‑1: Stone Management Device Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 8‑2: ESWL Equipment Market, U.S., 2020 – 2030 |
| Figure 8‑3: ISWL Equipment Market, U.S., 2020 – 2030 |
| Figure 8‑4: Holmium Laser Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 8‑5: Holmium Laser Equipment Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 8‑6: Total Holmium Laser Equipment Market, U.S., 2020 – 2030 |
| Figure 8‑7: High-Power Holmium Laser Equipment Market, U.S., 2020 – 2030 |
| Figure 8‑8: Low-Power Holmium Laser Equipment Market, U.S., 2020 – 2030 |
| Figure 8‑9: Holmium Laser Fiber Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 8‑10: Total Holmium Laser Fiber Market, U.S., 2020 – 2030 |
| Figure 8‑11: Reusable Holmium Laser Fiber Market, U.S., 2020 – 2030 |
| Figure 8‑12: Single-Use Holmium Laser Fiber Market, U.S., 2020 – 2030 |
| Figure 8‑13: Thulium Laser Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 8‑14: Thulium Laser Equipment Market, U.S., 2020 – 2030 |
| Figure 8‑15: Thulium Laser Fiber Market, U.S., 2020 – 2030 |
| Figure 8‑16: Stone Fragment Retrieval Device Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 8‑17: Total Stone Fragment Retrieval Device Market, U.S., 2020 – 2030 |
| Figure 8‑18: Nitinol Stone Fragment Retrieval Device Market, U.S., 2020 – 2030 |
| Figure 8‑19: Stainless-Steel Stone Fragment Retrieval Device Market, U.S., 2020 – 2030 |
| Figure 8‑20: Ureteral Stent Market, U.S., 2020 – 2030 |
| Figure 8‑21: Access Sheath Market Stent Market, U.S., 2020 – 2030 |
| Figure 8‑22: Leading Competitors, Stone Management Device Market, U.S., 2023 |
| Figure 9‑1: BPH Treatment Device Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 9‑2: TURP Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 9‑3: Monopolar Electrode Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 9‑4: Total Monopolar Electrode Market, U.S., 2020 – 2030 |
| Figure 9‑5: Monopolar Electrode Loop Market, U.S., 2020 – 2030 |
| Figure 9‑6: Monopolar Coagulating Resector Electrode Market, U.S., 2020 – 2030 |
| Figure 9‑7: Monopolar Vaporizing Electrode Market, U.S., 2020 – 2030 |
| Figure 9‑8: Other Monopolar Electrode Device Market, U.S., 2020 – 2030 |
| Figure 9‑9: Bipolar Electrode Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 9‑10: Total Bipolar Electrode Market, U.S., 2020 – 2030 |
| Figure 9‑11: Bipolar Electrode Loop Market, U.S., 2020 – 2030 |
| Figure 9‑12: Bipolar Vaporizing Electrode Market, U.S., 2020 – 2030 |
| Figure 9‑13: Other Bipolar Electrode Device Market, U.S., 2020 – 2030 |
| Figure 9‑14: TUMT Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 9‑15: TUMT Equipment Market, U.S., 2020 – 2030 |
| Figure 9‑16: TUMT Consumables Market, U.S., 2020 – 2030 |
| Figure 9‑17: TUNA Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 9‑18: TUNA Equipment Market, U.S., 2020 – 2030 |
| Figure 9‑19: TUNA Consumables Market, U.S., 2020 – 2030 |
| Figure 9‑20: Temporary Prostatic Stent Market, U.S., 2020 – 2030 |
| Figure 9‑21: Laser BPH Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 9‑22: Laser BPH Equipment Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 9‑23: Total Laser BPH Equipment Market, U.S., 2020 – 2030 |
| Figure 9‑24: High-Power Holmium Laser Equipment Market, U.S., 2020 – 2030 |
| Figure 9‑25: Thulium Laser Equipment Market, U.S., 2020 – 2030 |
| Figure 9‑26: Total Laser BPH Fiber Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 9‑27: Total Laser BPH Fiber Market, U.S., 2020 – 2030 |
| Figure 9‑28: Total Water Targeting Fiber Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 9‑29: Total Water Target Laser BPH Fiber Market, U.S., 2020 – 2030 |
| Figure 9‑30: Thulium BPH Fiber Market, U.S., 2020 – 2030 |
| Figure 9‑31: Thulium BPH Fiber Market, U.S., 2020 – 2030 |
| Figure 9‑32: Hemoglobin Target Laser BPH Fiber Market, U.S., 2020 – 2030 |
| Figure 9‑33: UroLift Market, U.S., 2020 – 2030 |
| Figure 9‑34: Total Rezūm® Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 9‑35: Rezūm® Equipment Market, U.S., 2020 – 2030 |
| Figure 9‑36: Rezūm® Consumables Market, U.S., 2020 – 2030 |
| Figure 9‑37: iTind Market, U.S., 2020 – 2030 |
| Figure 9‑38: Leading Competitors, BPH Treatment Device Market, U.S., 2023 |
| Figure 10‑1: Urological Endoscope Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 10‑2: Urological Endoscope Market by Condition, U.S., 2020 – 2030 (US$M) |
| Figure 10‑3: Urological Endoscope Market, U.S., 2020 – 2030 |
| Figure 10‑4: Cystoscope Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 10‑5: Total Cystoscope Market, U.S., 2020 – 2030 |
| Figure 10‑6: Single-Use Cystoscope Market, U.S., 2020 – 2030 |
| Figure 10‑7: Reusable Cystoscope Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 10‑8: Total Reusable Cystoscope Market, U.S., 2020 – 2030 |
| Figure 10‑9: Reusable Rigid Cystoscope Market by Condition, U.S., 2020 – 2030 (US$M) |
| Figure 10‑10: Total Reusable Rigid Cystoscope Market, U.S., 2020 – 2030 |
| Figure 10‑11: New Rigid Cystoscope Market, U.S., 2020 – 2030 |
| Figure 10‑12: Refurbished Rigid Cystoscope Market, U.S., 2020 – 2030 |
| Figure 10‑13: Reusable Flexible Cystoscope Market by Condition, U.S., 2020 – 2030 (US$M) |
| Figure 10‑14: Total Reusable Flexible Cystoscope Market, U.S., 2020 – 2030 |
| Figure 10‑15: New Flexible Cystoscope Market by Type, U.S., 2018 – 2028 (US$M) |
| Figure 10‑16: Total New Flexible Cystoscope Market, U.S., 2018 – 2028 |
| Figure 10‑17: New Flexible Fiber Optic Cystoscope Market, U.S., 2018 – 2028 |
| Figure 10‑18: New Flexible Digital Cystoscope Market, U.S., 2020 – 2030 |
| Figure 10‑19: Reusable Refurbished Flexible Cystoscope Market by Type, U.S., 2020 – 2030 (US$M) |
| Figure 10‑20: Total Refurbished Flexible Cystoscope Market, U.S., 2018 – 2028 |
| Figure 10‑21: Refurbished Flexible Fiber Optic Cystoscope Market, U.S., 2020 – 2030 |
| Figure 10‑22: Refurbished Flexible Digital Cystoscope Market, U.S., 2020 – 2030 |
| Figure 10‑23: Ureteroscope Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 10‑24: Total Ureteroscope Market, U.S., 2020 – 2030 |
| Figure 10‑25: Single-Use Flexible Ureteroscope Market, U.S., 2020 – 2030 |
| Figure 10‑26: Reusable Ureteroscope Market by Segment, U.S., 2018 – 2028 (US$M) |
| Figure 10‑27: Total Reusable Ureteroscope Market, U.S., 2020 – 2030 |
| Figure 10‑28: Reusable Semi-Rigid Ureteroscope Market by Condition, U.S., 2020 – 2030 (US$M) |
| Figure 10‑29: Total Reusable Semi-Rigid Ureteroscope Market, U.S., 2020 – 2030 |
| Figure 10‑30: New Semi-Rigid Ureteroscope Market, U.S., 2020 – 2030 |
| Figure 10‑31: Refurbished Semi-Rigid Ureteroscope Market, U.S., 2020 – 2030 |
| Figure 10‑32: Reusable Flexible Ureteroscope Market by Device Type, U.S., 2020 – 2030 (US$M) |
| Figure 10‑33: Reusable Flexible Ureteroscope Market by Condition, U.S., 2020 – 2030 (US$M) |
| Figure 10‑34: Total Reusable Flexible Ureteroscope Market, U.S., 2020 – 2030 |
| Figure 10‑35: Flexible Fiber Optic Ureteroscope Market, U.S., 2020 – 2030 |
| Figure 10‑36: Flexible Digital Ureteroscope Market, U.S., 2020 – 2030 |
| Figure 10‑37: New Flexible Ureteroscope Market, U.S., 2020 – 2030 |
| Figure 10‑38: Refurbished Flexible Ureteroscope Market, U.S., 2020 – 2030 |
| Figure 10‑39: Refurbished Flexible Fiber Optic Ureteroscope Market, U.S., 2020 – 2030 |
| Figure 10‑40: Refurbished Flexible Digital Ureteroscope Market, U.S., 2020 – 2030 |
| Figure 10‑41: Resectoscope Market by Segment, U.S., 2018 – 2028 (US$M) |
| Figure 10‑42: Total Resectoscope Market, U.S., 2018 – 2028 |
| Figure 10‑43: New Resectoscope Market, U.S., 2020 – 2030 |
| Figure 10‑44: Refurbished Resectoscope Market, U.S., 2020 – 2030 |
| Figure 10‑45: Nephroscope Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 10‑46: Total Nephroscope Market, U.S., 2018 – 2028 |
| Figure 10‑47: New Nephroscope Market, U.S., 2020 – 2030 |
| Figure 10‑48: Refurbished Nephroscope Market, U.S., 2020 – 2030 |
| Figure 10‑49: Leading Competitors, Urological Endoscope Market, U.S., 2023 |
| Figure 11‑1: Prostate Cancer Treatment Device Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 11‑2: Brachytherapy Device Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 11‑3: HDR Brachytherapy Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 11‑4: Afterloader Market, U.S., 2020 – 2030 |
| Figure 11‑5: Afterloader Service Market, U.S., 2020 – 2030 |
| Figure 11‑6: LDR Brachytherapy Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 11‑7: LDR Seed Market by Isotope, U.S., 2020 – 2030 (US$M) |
| Figure 11‑8: LDR Seed Market by Seed Type, U.S., 2030 – 2030 (US$M) |
| Figure 11‑9: Total LDR Seed Market, U.S., 2020 – 2030 |
| Figure 11‑10: Cs-131 Market by Seed Type, U.S., 2020 – 2030 (US$M) |
| Figure 11‑11: Total Cs-131 Market, U.S., 2020 – 2030 |
| Figure 11‑12: Stranded Cs-131 Market, U.S., 2020 – 2030 |
| Figure 11‑13: Non-Stranded Cs-131 Market, U.S., 2020 – 2030 |
| Figure 11‑14: Pd-103 Market by Seed Type, U.S., 2020 – 2030 (US$M) |
| Figure 11‑15: Total Pd-103 Market, U.S., 2020 – 2030 |
| Figure 11‑16: Stranded Pd-103 Market, U.S., 2020 – 2030 |
| Figure 11‑17: Non-Stranded Pd-103 Market, U.S., 2020 – 2030 |
| Figure 11‑18: I-125 Market by Seed Type, U.S., 2020 – 2030 (US$M) |
| Figure 11‑19: Total I-125 Market, U.S., 2020 – 2030 |
| Figure 11‑20: Stranded I-125 Market, U.S., 2020 – 2030 |
| Figure 11‑21: Non-Stranded I-125 Market, U.S., 2020 – 2030 |
| Figure 11‑22: LDR Needle Market, U.S., 2020 – 2030 |
| Figure 11‑23: Cryotherapy Ablation Device Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 11‑24: Cryotherapy Ablation Device Market, U.S., 2020 – 2030 |
| Figure 11‑25: Cryotherapy Ablation Device Rental Market, U.S., 2020 – 2030 |
| Figure 11‑26: Cryotherapy Ablation Probe Market, U.S., 2020 – 2030 |
| Figure 11‑27: Hydrogel Rectal Spacer Device Market, U.S., 2020 – 2030 |
| Figure 11‑28: Leading Competitors, Prostate Cancer Treatment Device Market, U.S., 2023 |
| Figure 11‑29: Leading Competitors, Brachytherapy Device Market, U.S., 2023 |
| Figure 12‑1: Urodynamic Equipment Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 12‑2: Urodynamic Equipment Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 12‑3: Total Urodynamic Equipment Market, U.S., 2020 – 2030 |
| Figure 12‑4: Hospital Urodynamic Capital Equipment Market, U.S., 2020 – 2030 |
| Figure 12‑5: Medical Office Urodynamic Capital Equipment Market, U.S., 2020 – 2030 |
| Figure 12‑6: Total Urodynamic Consumables Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 12‑7: Total Urodynamic Consumables Market, U.S., 2020 – 2030 |
| Figure 12‑8: Air-Charged Catheter Market, U.S., 2020 – 2030 |
| Figure 12‑9: Water-Filled Catheter Market, U.S., 2020 – 2030 |
| Figure 12‑10: Fiber Optic Catheter Market, U.S., 2020 – 2030 |
| Figure 12‑11: Leading Competitors, Urodynamic Equipment Market, U.S., 2023 |
| Figure 13‑1: Nephrostomy Device Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 13‑2: Percutaneous Nephrostomy Set Market, U.S., 2020 – 2030 |
| Figure 13‑3: Nephrostomy Balloon Catheter Market, U.S., 2020 – 2030 |
| Figure 13‑4: Nephrostomy Drainage Tube Market, U.S., 2020 – 2030 |
| Figure 13‑5: Leading Competitors, Nephrostomy Device Market, U.S., 2023 |
| Figure 14‑1: Men’s Reproductive Health Market by Segment, U.S., 2020 – 2030 (US$M) |
| Figure 14‑2: Inflatable Erectile Dysfunction Device Market, U.S., 2020 – 2030 |
| Figure 14‑3: Malleable Erectile Dysfunction Device Market, U.S., 2020 – 2030 |
| Figure 14‑4: Vacuum Erection Device Market, U.S., 2020 – 2030 |
| Figure 14‑5: Testicular Implant Market, U.S., 2020 – 2030 |
| Figure 14‑6: Leading Competitors, Men’s Reproductive Health Market, U.S., 2023 |
| Figure 15‑1: Urinary Guidewire Market, U.S., 2020 – 2030 |
| Figure 15‑2: Leading Competitors, Urinary Guidewire Market, U.S., 2023 |
In 2023, Boston Scientific emerged as a dominant force in the urological device market. The company took the lead in stone management devices, prostate cancer treatments, and men’s reproductive health. Excluding its non-involvement in urodynamics, Boston Scientific held substantial market shares across other urology-related segments. The company has strategically positioned itself as a comprehensive provider for hospital urology departments through significant acquisitions and enhancements. Key acquisitions include Augmenix and Galil Medical in the prostate cancer arena and Lumenis in laser treatments. Noteworthy innovations by Boston Scientific include the introduction of the LithoVue™, a single-use flexible ureteroscope in 2016, and the SpaceOar hydrogel, which, since its FDA approval in 2015 and acquisition of Augmenix in 2018, has seen widespread adoption.
